3 results match your criteria: "Department of Urology Aichi Cancer Center Hospital Nagoya Aichi Japan.[Affiliation]"
Article Synopsis
- A 36-year-old male diagnosed with advanced testicular cancer successfully resumed chemotherapy after contracting mild COVID-19 during treatment.
- Despite the diagnosis, the delay in treatment was minimal, allowing the patient to achieve remission.
- The case highlights the importance of individualized decision-making regarding chemotherapy resumption in cancer patients infected with COVID-19, considering various factors such as cancer progression and illness severity.
Introduction: Prostate cancer with a microsatellite instability-high or mismatch repair-deficient status is not common. Few reports of the response to pembrolizumab in metastatic castration-resistant prostate cancer in a real-world setting have been reported. This case report describes a dramatic response to pembrolizumab after initial pseudoprogression in a patient with microsatellite instability-high metastatic castration-resistant prostate cancer.
View Article and Find Full Text PDF